|
Post by cm5 on Apr 21, 2016 17:23:45 GMT -5
Average price of EpiPen for those without insurance coverage: >$600.
|
|
|
Post by cm5 on Apr 20, 2016 17:20:48 GMT -5
Hmm, speaking here as someone with anaphylaxis, I ask the following: - How many naysayers re: epinephrine in Technosphere have ever jabbed themselves in the thigh with an EpiPen, while suffering at the same time with the sense of impending doom, being distressed that the injector might not work right, fearful that one might drop the injector, and hating how much the forceful jab of the needle is going to hurt, and thinking "Do I really need to do it this time?"
- In other words, until you have lived anaphylaxis and tried to find your EpiPen, and realized you did not bring it that day because it was too big for your jacket pocket, or it was in your briefcase in another office or the conference room, or it's expired, and suddenly you life is fading away----
- In other words, this is a enormous issue of possible death, if not a miserable experience waiting for EMT's, or a long night in an ER when a pocket sized Technosphere filled with epinephrine could have stopped progression to circulatory collapse, obstruction of airway, and consequent intubation and IV Solution-Medrol.
- There is a enormous unmet need for convenient self medication with epinephrine when one is aware that anaphylaxis is a possibility or probable.
|
|
|
Post by cm5 on Apr 17, 2016 20:07:09 GMT -5
Thank You for The Thank You. I seem a "newbie", finally joined last year when everything seemed dire, have rarely posted, but have been watching/reading for a very long time---years. Patient is a strength and a virtue, as well as mandatory when waiting for disruptive technology to emerge. I am an MD, not in primary care nor an endocrinologist, but I diagnose and care for the consequences of pre-diabetes and undiagnosed diabetes, as well as untreated elevated HgbA1c levels. Daily I am concerned and upset about what I see happening to my patients. I remain convinced that Alfred Mann is the genius of our time, and that his efforts will lead to amazing improvements in the health of people worldwide----whether it be sooner or later than we all expect.
|
|
|
Post by cm5 on Apr 17, 2016 11:45:45 GMT -5
Feb 28, 2016 19:23:30 GMT -4 mnholdem said: patents.justia.com/patent/9259471Example 11 Oral Administration of Disodium FDKP-Insulin Capsules containing the FDKP salt and insulin are taken before a meal. The exact dosage is patient-specific, but generally on the order of 10-150 units of insulin is administered per dose. This oral insulin formulation is used to replace pre-meal insulin injections in patients with diabetes. Additionally, insulin absorbed through the gastrointestinal tract mimics endogenous insulin secretion. Endogenous insulin is secreted by the pancreas into the portal circulation. Thus, the oral route of insulin administration delivers insulin to the site of action in the liver, offering the potential to control glucose levels while limiting systemic exposure to insulin. Oral insulin delivery using a combination of insulin and the diacid form of FDKP is hindered by the poor solubility of the FDKP diacid in the low PH environment of the gastrointestinal tract. The FDKP salts, however, provide a local buffering effect that facilitates their dissolution in low PH. --- There is more, but this could be BIG NEWS to shareholders. Date of patent: February 16, 2016 Filed:January 8, 2014 --- Note: Andrea Leone-Bay is listed as one of three inventors.
|
|
|
Post by cm5 on Apr 17, 2016 11:02:33 GMT -5
See Peppy's post 6 March 2016 Oral Administration of Disodium FDKP-Insulin Capsules containing the FDKP salt and insulin are taken before a meal. The exact dosage is patient-specific, but generally on the order of 10-150 units of insulin is administered per dose. This oral insulin formulation is used to replace pre-meal insulin injections in patients with diabetes. Additionally, insulin absorbed through the gastrointestinal tract mimics endogenous insulin secretion. Endogenous insulin is secreted by the pancreas into the portal circulation. Thus, the oral route of insulin administration delivers insulin to the site of action in the liver, offering the potential to control glucose levels while limiting systemic exposure to insulin. Oral insulin delivery using a combination of insulin and the diacid form of FDKP is hindered by the poor solubility of the FDKP diacid in the low PH environment of the gastrointestinal tract. The FDKP salts, however, provide a local buffering effect that facilitates their dissolution in low PH. Read more: mnkd.proboards.com/thread/5250/mannkind-got-oral-insulin-patent?page=1#ixzz42Aw7eeYk
|
|
|
Post by cm5 on Jan 9, 2016 11:06:55 GMT -5
Not only would it be tragic if the world's diabetics, to say nothing of their families and communities, were cheated of Afrezza, but it would also be criminal. Read about the Norfolk States' Women's Basketball player, Amber Brown, who was found unconscious in her dorm room after team mates and the coach became concerned when this dedicated young woman did not arrive for practice. She is now in critical condition in ICU, comatose, having suffered seizures, two heart attacks, and a brain bleed from diabetic hypoglycemia. wtkr.com/2016/01/07/norfolk-state-womens-basketball-player-hospitalized-in-coma/
|
|
|
Post by cm5 on Aug 30, 2015 17:24:28 GMT -5
"Insulin resistance and lower glucose uptake were especially robustly associated in the left medial temporal lobe (R2 = 0.178; P < .05), and lower glucose metabolism in this lobe was associated with worse immediate and delayed memory performance factors (P < .001 for both). “This finding provides a potential link between insulin resistance and cognitive decline,” they wrote.
The findings also support results from previous studies of older adults that have linked insulin resistance, hyperglycemia, and diabetes mellitus to hypometabolism on FDG-PET. “Insulin resistance and hyperglycemia are related conditions, and hyperglycemia, even in the prediabetic range, is associated with a significantly increased risk for later development of dementia,” they noted."
This article does not specifically discuss HgbA1C levels, so here at the levels for Normal, Pre-Diabetes, and Diabetes:
A1C
Normal less than 5.7%
Prediabetes 5.7% to 6.4%
Diabetes 6.5% or higher
Inflammation due to hyperglycemia is postulated to be a possible underlying cause of AD (Alzheimer's Disease).
In other words, achieving lower A1C levels, which Afrezza users are demonstrating, may decrease the chances of developing AD.
|
|